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Context: Diabetes is associated with increased incidence of atherothrombotic disease. The fibrin
network forms the backbone of the arterial thrombus, and fibrin clot structure determines pre-
disposition to cardiovascular events.
Objectives: The aim of the study was to investigate fibrin clot structure/fibrinolysis in the largest
type 2 diabetes cohort and analyze associations with cardiometabolic risk factors and vascular
pathology.
Design:Clot structure/fibrinolysiswasassessed in875participantsof theEdinburghType2Diabetes
Study [age, 68 (range, 60–75) yr; 450 males] by turbidimetric assays, and clots were visualized by
confocal microscopy. Four parameters of clot structure/fibrinolysis were analyzed, and plasma
levels of fibrinogen and plasminogen activator inhibitor-1 were studied by Clauss assay and ELISA,
respectively.
Results: Clot maximum absorbance was increased in females compared with males (0.37  0.005
and0.340.005arbitraryunit, respectively;P0.001), and took longer to lyse (80320and665
12 sec, respectively; P 0.001). These gender differences in clot structure and fibrinolysis were still
evident after correcting for fibrinogen and plasminogen activator inhibitor-1 plasma levels. A
prothrombotic fibrin structure profile was associated with increased body mass index and low
levels of high-density lipoprotein in women and with inadequate diabetes control in men. Clot
formation time was related to previous cardiac ischemic events in both men and women after
adjusting for traditional risk factors [odds ratio, 1.22 (95%confidence interval, 1.07, 1.38); and1.33
(1.15, 1.50), respectively], and prothrombotic clots were associated with low ankle brachial index,
renal impairment, and smoking, regardless of gender.
Conclusions:Womenwith type 2 diabetes have compact clots with compromised fibrinolysis com-
pared with men. There are gender-specific associations between clotting parameters and cardio-
metabolic risk factors in this population, whereas vascular abnormalities, impaired renal function,
and smoking are associated with prothrombotic clot structure profile regardless of gender. (J Clin
Endocrinol Metab 97: E2282–E2287, 2012)
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Atherothrombotic disease remains the main cause ofmortality in subjects with type 2 diabetes (T2DM)
(1). An occlusive arterial thrombus consists of a skeleton
of fibrin fibers, the structure of which influences predis-
position to cardiovascular disease (2).Only a limitednum-
ber of studies investigated the effects of diabetes on fibrin
structure and demonstrated an association with compact
clots and resistance to fibrinolysis (3–5), although thiswas
less clear in smaller studies involving T2DM subjects (6, 7).
In addition to the limited number of samples analyzed, a
collective criticism of T2DM studies is incomplete charac-
terization of this highly heterogeneous group of individuals,
making results interpretation inconclusive. Also, the rela-
tionship between clot structure and metabolic parameters,
cardiovascular risk factors, and the presence of vascular pa-
thology has not been appropriately addressed. Therefore,
there is a gap in the literature in relation to characterization
ofclot structure inT2DM,which iscrucial forunderstanding
the role of the fibrin network in predisposition to athero-
thrombotic events in this common condition.
Our aim was to study fibrin clot structure/fibrinolysis
in a large cohort ofwell-characterizedT2DMsubjects.We
have analyzed the effects of gender, age, metabolic and
cardiac parameters, current vascular pathology, and pre-
vious history of ischemic heart disease (IHD) on multiple
fibrin clot parameters.
Subjects and Methods
Study population and examination
The study protocol of the Edinburgh Type 2 Diabetes Study
is described elsewhere, including criteria used for thediagnosis of
macrovascular complications (8). Briefly, 1066 patients with
T2DM (age, 60–75 yr) were randomly recruited; they are rep-
resentative of those invited to participate (n 5454) (9). A total
of 875 plasma samples were available for clot structure analysis.
Analysis of clot formation/lysis and plasma levels
of coagulation proteins
Blood samples were taken into citrated tubes without a tour-
niquet after a 4-h fast, usually atmidday. The first 5mlwere used
for clinical tests and platelet poor plasma separated from sub-
sequent samples with clot turbidity and lysis measurements con-
ducted as previously described (10). Several variables were re-
corded that show associationswith cardiovascular risk (10–13),
including lag phase, clot maximum absorbance, clot formation
time, and lysis time. Fibrinogen and plasminogen activator in-
hibitor-1 (PAI-1) plasma levels were measured as described (4).
Laser scanning confocal microscopy
Fibrin clots were prepared from pooled plasma of ran-
domly selected samples (10 female and 10 male subjects) as
described (4).
Statistical analysis
Exploratory analysis was done using SPSS program version
16 (SPSS Inc., Chicago, IL). Statistical modeling was done using
Rprogramversion 2.15 (r-project.org). Between-group compar-
isons of normally distributed variables were carried out using t
test, whereas comparisons of nonnormally distributed variables
were carried out by Mann-Whitney test. Differences between
categorical variables were analyzed by 2 test. Logistic and mul-
tiple regressionmodels were used to identify clotting parameters
associated with vascular disease and cardiometabolic factors as-
sociated with clotting parameters.
Results
Subject characteristics
Demographic/clinical characteristics of the study pop-
ulation are summarized in Table 1.
Female gender is associated with a prothrombotic
fibrin network profile
Female gender was associatedwith longer clot formation
time compared with males, which may be related to higher
maximumabsorbanceand/or longerclot lysis time (Table1).
Plasma fibrinogen levels were higher in females than males,
but differences in fibrin clot parameters remained after ad-
justing for protein levels. Similarly, PAI-1 was higher in
women than men, and the difference in lysis time was still
present after adjusting forPAI-1 levels.Genderdifferences in
clot structure remained after correcting for bodymass index
(BMI), indicating that these are not related to higher BMI in
women.Differencesbetweenmaleand female clotswere fur-
ther visually confirmed by laser scanning confocal micros-
copy (Fig. 1A, upper panel).
Clot formation time showed significant correlationswith
both fibrinogen and PAI-1 levels (P 0.001 for both), indi-
cating that it reflects both thrombosis and fibrinolysis po-
tential. For comparison, lysis time mainly correlated with
PAI-1 levels, whereas clot maximum absorbance correlated
with fibrinogen levels. Given gender differences, further
analysis was conducted separately for men and women.
Older age is associated with denser clots and
enhanced fibrinolysis in men
In men, clot maximum absorbance increased with age,
whereas lysis shortened, associated with a trend toward
higher PAI-1 plasma levels in younger men (921 71 and
738  64 pg/ml for lower and higher tertiles of age, re-
spectively;P 0.06). The effect of agewas independent of
vascular pathology measured as ankle brachial index
(ABI) or intima media thickness (IMT) (detailed in the
section entitled Clot structure/fibrinolysis is altered in the
presence of clinical and subclinical vascular disease). In
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women, age had no effect on clot structure parameters
(Fig. 1A) or plasma levels of clotting factors.
Association of anthropometric, metabolic, and
renal factors with clot structure parameters
Waist circumference (WCF)
Clotmaximumabsorbancewas increased in the high-
est tertile ofWCFs compared with the lowest in women,
and lysis time was longer, which did not apply to men
(Fig. 1B). Similar results were obtained for BMI (data
not shown).
Glycated hemoglobin (HbA1c)
Glycemic control affected clot density in men only be-
cause maximum absorbance was increased in the highest
tertile of HbA1c compared with the lowest (Fig. 1B).
High-density lipoprotein (HDL) cholesterol
The lowest HDL tertile in women showed longer clot
formation time compared with highest tertile, with a
similar pattern observed for maximum absorbance and
lysis time. HDL levels failed to correlate with clotting
parameters in men (Fig. 1B).
Renal factors
Clot formation time was longer and maximum absor-
bance higher in the lowest estimated glomerular filtration
rate (eGFR) tertile compared with the highest in both men
and women (Fig. 1B).
Smoking has additional effect on clot structure
parameters in T2DM
Maximum absorbance was higher in current smokers
than nonsmokers in both men [0.37 0.014 and 0.32
0.009 arbitrary unit (au); P 0.008] and women (0.41
0.018 and 0.37 0.009 au;P 0.04). Inmen, time to full
clot formation was longer in smokers than nonsmokers
(572  16 and 509  11 sec; P  0.002), whereas in
TABLE 1. Clinical characteristics, clot structure parameters, and coagulation factor plasma levels by gender
Variable Male Female P value
n 450 425 0.39
Age, yr (range) 68.2 (60–75) 67.9 (60–75) 0.34
Duration of T2DM (yr) 8.33  0.31 7.75  0.31 0.31
Current smokers, n (%) 65 (14) 47 (11) 0.27
Vascular parameters
IHD, n (%) 164 (36) 100 (24) 0.001
Systolic BP (mm Hg) 133  0.7 133  0.8 0.58
Diastolic BP (mm Hg) 70  0.4 68  4 0.001
IMT (mm) 1.04  0.01 0.96  0.01 0.001
ABI 1.01  0.01 0.96  0.007 0.001
Anthropometrics
BMI (kg/m2) 30.2  0.2 32.5  0.3 0.001
Waist circumference (cm) 107.9  0.5 113.8  0.6 0.004
Waist/hip ratio 1.00  0.003 0.93  0.003 0.001
Metabolic and renal
HbA1c (%) 7.33  0.06 7.46  0.06 0.16
Plasma glucose (mmol/liter) 7.6  0.1 7.5  0.1 0.56
Total cholesterol (mmol/liter) 4.2  0.04 4.5  0.05 0.001
HDL cholesterol (mmol/liter) 1.16  0.016 1.34  0.017 0.001
eGFR (ml/min  m2) 66.0  0.7 61.7  0.7 0.001
Treatment, n (%)
Metformin 285 (63) 240 (56) 0.09
Aspirin 310 (69) 261 (61) 0.06
Insulin 43 (10) 51 (12) 0.39
Thiazolidinediones 72 (16) 73 (17) 0.77
ACEi  ARB 317 (70) 274 (64) 0.13
Statins 332 (74) 316 (74) 0.91
Sulfonylurea 125 (28) 114 (27) 0.84
Nitrates 85 (19) 69 (16) 0.43
Clot structure parameters
Lag phase (sec) 528  6 520  6 0.37
Maximum absorbance (au) 0.34  0.005 0.37  0.005 0.001
Clot formation time (sec) 516  7 562  6 0.001
Lysis time (sec) 665  12 803  20 0.001
Plasma protein levels
Fibrinogen (mg/ml) 3.50  0.03 3.77  0.03 0.01
PAI-1 (pg/ml) 797  38 1081  50 0.01
Data are presented as mean  SEM or absolute number (percentage). To control for false discovery rate, adjustments have been made for multiple
testing. BP, Blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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women only a trend was observed (586  20 and 551 
8 sec; P  0.06).
Clot structure/fibrinolysis is altered in the
presence of clinical and subclinical vascular disease
Ischemic heart disease
Men with IHD (n 164) had higher clot maximum ab-
sorbance compared with those without (0.35  0.008 and
0.33 0.006 au; P 0.05) and longer clot formation time
(573 15 and 522 7 sec;P 0.05), with a trend detected
in women (n 100; 575 18 and 548 6 sec; P 0.07).
Ankle brachial index
Comparing the lowest and highest tertile of ABI, dif-
ferences in clot structure parameters were found regard-
less of gender (Supplemental Fig. 1, published on The
Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
Carotid IMT
IMT demonstrated no significant associations with
clot structure parameters in men or women (Supple-
mental Fig. 1).
To assess the role of clot structure in IHD in the pres-
ence of traditional risk factors (history of smoking, total
cholesterol, HDL, systolic and diastolic blood pressure,
HbA1c, andage),multiple regressionmodelswereused, to
include each clotting parameter and fibrinogen/PAI-1 lev-
els.Clot formation timewas associatedwithprevious IHD
FIG. 1. The effects of gender, age, anthropometric, metabolic, and vascular parameters on clot structure fibrinolysis in T2DM. A, Upper panel
represents confocal microscopy of clots made from pooled plasma samples of male and female subjects (n  10 each). Lower panels show the
effects of age, ranked in ascending tertiles, on clot structure parameters. B, Clot structure parameters in relation to WCF, HbA1c, HDL cholesterol,
and eGFR, ranked in ascending tertiles.
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in men and women [odds ratio, 1.22 (95% confidence
interval, 1.07, 1.38) and 1.33 (1.15, 1.50), for 100 sec
change, respectively; P  0.01 for both] (Supplemental
Fig. 2).
Discussion
In addition to the large cohort, an advantage of this work
is the dynamic analysis of clot formation/lysis, giving a
global assessment of fibrin-related thrombosis risk, which
studies investigating plasma levels/activity of coagulation
proteins fail to provide (14). Several novel findings emerge
from this work: 1) women with T2DM have a prothrom-
botic fibrin profile that exhibits gender-specific associa-
tions with anthropometric and metabolic factors; 2) indi-
viduals with a history of vascular ischemia or evidence of
subclinical vascular disease have prothrombotic clots; and
3) impaired renal function or smoking is associated with
additional adverse effects on clot structure and fibrinolysis
in T2DM.
The denser fibrin clots and resistance to fibrinolysis in
women, which is not fully explained by fibrinogen or
PAI-1 levels, may contribute to the loss of cardiovascular
protection in females with diabetes (15). Gender differ-
ences in clotting parameters extended tometabolic factors
because raised WCF/BMI and low HDL were associated
with prothrombotic clot phenotype in women, whereas
hyperglycemia was associated with an adverse clot profile
in men. Age also had a gender effect, with higher clot
maximum absorbance in older men coupled with a para-
doxical enhancement in fibrinolysis, whichmay be related
to a trend toward lower PAI-1 levels, an observation that
has been recently documented (16). Clinically, these data
suggest that womenwith T2DMand increasedWCF/BMI
or low HDL and men with poor glycemic control are at
higher atherothrombotic risk and may require more ag-
gressive antithrombotic therapy. In contrast, enhanced fi-
brinolysis in older men with T2DM may be associated
with increased bleeding risk, calling for careful assessment
of antithrombotic therapy. This proposes individualized
antithrombotic therapy in T2DM to maximize benefits
and minimize bleeding risks.
IHDwasassociatedwithprothrombotic clots, support-
ing previouswork inmixed diabetic and nondiabetic pop-
ulations (12, 13). Clot formation timewas an independent
predictor of previous ischemic history in both men and
women, with a 1% increase in this clotting parameter as-
sociated with a 1% increase in odds ratio for IHD, indi-
cating that this measure may be an additional novel
marker of cardiovascular disease. The association be-
tween vascular pathology and clot structure parameters
was further evidenced by the relationship between ABI
and clot structure. This supports clinical studies demon-
strating high risk of vascular occlusive events in individ-
uals with peripheral artery disease (17). In contrast, IMT
failed to showassociationswith clot structure parameters.
The discrepancy between ABI and IMT is not unprece-
dented and can be explained by the relatively weak cor-
relation between these vascular parameters, which can be
influenced by the IMT measurement taken (18, 19). In
addition to vascular factors, low eGFR and smoking were
associated with deleterious effects on clot structure, sup-
porting previous findings (11, 20) and suggesting addi-
tional prothrombotic effects for impaired renal function
and smoking in diabetes.
Although these findings have potential clinical implica-
tions, there are limitations to be acknowledged. First, inves-
tigating plasma fibrin networks ex vivo ignores the potential
influence of platelets, endothelial, or smoothmuscle cells on
clot properties. Second, the study was carried out at a single
time point, and therefore cause-effect relationship is not
proven and further longitudinal work is needed to assess the
role of clot structure in predicting vascular events in T2DM,
a study that is currently ongoing.Third, it is unclearwhether
demonstrated gender differences are specific for the popula-
tion studied andwhether healthy individuals display similar
findings. However, the study aim was to comprehensively
characterize clot structureparameters inT2DM,andrecruit-
ing a large control group devoid of clinical disease has prac-
tical limitations, given the age of the cohort studied.
In conclusion, femaleswithT2DMdisplay a prothrom-
botic fibrin profile compared with males, and gender dif-
ferences are evident in relation to cardiometabolic mark-
ers. This suggests that fibrin-related thrombosis risk
should be assessed separately for men and women with
T2DM,whichmay translate clinically into gender-specific
treatment strategies. Of the parameters studied, clot for-
mation time may represent a novel cardiovascular risk
predictor inT2DM,butprospective studies are required to
test thismarker.Our findings also indicate that peripheral
arterial disease, renal impairment, and smoking all confer
additional adverse thrombotic effects in T2DM.
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